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Immunological considerations and challenges
for regenerative cellular therapies
Sandra Petrus-Reurer 1,4✉, Marco Romano 2,4, Sarah Howlett3,
Joanne Louise Jones 3, Giovanna Lombardi 2 & Kourosh Saeb-Parsy 1✉
The central goal of regenerative medicine is to replace damaged or diseased tissue with cells
that integrate and function optimally. The capacity of pluripotent stem cells to produce
unlimited numbers of differentiated cells is of considerable therapeutic interest, with several
clinical trials underway. However, the host immune response represents an important barrier
to clinical translation. Here we describe the role of the host innate and adaptive immune
responses as triggers of allogeneic graft rejection. We discuss how the immune response is
determined by the cellular therapy. Additionally, we describe the range of available in vitro
and in vivo experimental approaches to examine the immunogenicity of cellular therapies,
and finally we review potential strategies to ameliorate immune rejection. In conclusion, we
advocate establishment of platforms that bring together the multidisciplinary expertise and
infrastructure necessary to comprehensively investigate the immunogenicity of cellular
therapies to ensure their clinical safety and efficacy.
Regenerative medicine has emerged as a promising strategy to restore damaged or diseasedcells and tissues as a consequence of aging, disease, injury, or accidents. Typically, thesetherapies involve deriving cell types of interest from an undifferentiated source of cells
with multi- or pluripotency, including human embryonic (hESC) or induced (hiPSC) pluripotent
stem cell origin1. Following a thorough assessment of specific marker expression, morphology,
and functionality of the derived cells in vitro, pre-clinical studies are necessary to assess the
survival, integration, safety, and efficacy of the cell product. There are numerous diseases without
current curative treatment such as age-related macular degeneration, Parkinson’s disease, Type 1
Diabetes Mellitus, and liver disease that could be transformed by the application of cellular
therapies to restore tissue function. In fact, currently more than 20 phase I/II stem cell-based
studies are registered on ClinicalTrials.gov, but only a few have published results showing
survival and safety of the tested cellular therapies; efficacy outcomes are, therefore, awaited
(Table 1).
Despite the fact that some cellular therapies have progressed to clinical trials, their immu-
nogenicity remains an unresolved challenge that may impede effective long-term translation to
the clinic. Although it is often assumed that autologous hiPSCs (i.e., isogenic grafts) lack
immunogenicity, this may be dependent on cell type2–5. Alternatively, stem cell-derivatives
generated from individuals unrelated to the recipient (i.e., allogeneic grafts) are very likely to lead
to immune-mediated rejection due to their allogeneic origin. Different strategies are in place to
reduce graft rejection, including the use of immunosuppressants and human leukocyte antigen
(HLA) matching between donor and recipient6,7, but none are entirely successful at abolishing
the immune response in a non-toxic manner. Understanding the mechanisms triggering the
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immune response toward a cellular product remains key to
minimizing rejection and ensuring long-term graft survival and
function.
What are the dominant drivers of the immune response to
stem cell therapies?
The immune response is orchestrated by the innate and adaptive
immune systems. The first line of defense or the innate immune
response consists of fast (0–96 h) and usually non-specific phy-
sical, chemical, and cellular responses against pathogens. The
second line of defense or the adaptive immune response also
referred to as acquired immunity, is only found in vertebrates and
is long-lasting. Although innate and adaptive immune responses
are often considered as sequential and separate, there is now
increasing recognition that there is an overlap between the two,
both mechanistically and in timelines (Table 2).
Many of the pathways and processes in innate immunity are
the same as those responsible for non-specific reactions to tissue
damage, resulting in inflammation. Therefore, tissue stress and
inflammation that can occur at the time of transplantation of
regenerative cellular therapies is predominantly mediated by the
innate immune system.
Natural killer cells (NKs), a key component of the innate
immune system, are thought to play an important role in
allogeneic cellular product rejection (Fig. 1 and Table 2). NKs
specifically target and kill cells that express mismatched/lack self-
human leukocyte antigen class I (HLA-I, also known as major
histocompatibility complex [MHC]) molecules (“missing-self”
Table 1 Main registered clinical trials with stem-cell-derived products for regenerative medicine.
Type of cells Disease Format Clinical trial id
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Table 2 Main components, dominant stimuli, and effector functions of the innate and adaptive immune response to regenerative
cellular therapies.
Main component Dominant stimuli Effector functions
Innate immune system PAMP and DAMP – Damage-associated molecular patterns
(DAMP) and Pathogen-associated
molecular patterns (PAMP) via pattern
recognition receptors (PRR)8
– Immune cell recruitment
– Cytokine and chemokine release
Fast (0–96 h) and usually non-specific physical,




NK Cell – NK cell activated by lack of self HLA class-
I (HLA-I), mediated by inhibitory and
activating molecules including DNAX
Accessory Molecule-1 (DNAM-1) receptor
and killer-cell immunoglobulin-like
receptors (KIR)9,10
– Direct lysis and cytotoxicity through
perforin, granzymes, and tumor
necrosis factor (TNF) family effector
molecules (Fig. 1)
– Release of pro-inflammatory cytokines
– Recognition and killing of target cells
opsonized with antibodies via low-
affinity IgG receptor CD16 receptor
Complement and coagulation
system
– Direct activation by pathogens or
indirectly by pathogen-bound antibodies
– Membrane attack by rupturing cell
wall (classical complement pathway)
– Phagocytosis by opsonizing antigens
(alternative complement pathway)
– Inflammation by attracting
macrophages and neutrophils (lectin
pathway)
Dendritic Cell – Direct by recognition of alloantigens/
pathogen molecules (PAMP and DAMP)
– Indirectly by inflammatory mediators and
cytokines
– Activation of CD4+ T helper cells and
the innate immune system
Adaptive immune system CD4+ T Helper Cell – Recognition of foreign/mismatched donor
antigens via alloantigen-HLA-II-TCR
complex34,35
– Direct, semi-direct or indirect
pathways of allorecognition37:
activation of other immune cells
including cytotoxic T cells, B cells, and
NK cells (Fig. 2)
Antigen-specific and reacts to a broad range of
microbial and non-microbial foreign substances or
antigens; quick and vigorous response with repeated
exposure to the same antigen (memory)
Three signals for T cell
activation34:
Interaction between HLA and
the T cell receptor (TCR)
Provided by APC expression of
co-stimulatory molecules B7.1
[CD80] or B7.2 [CD86]
Release of specific cytokines,
which also determines CD4+ T
cell commitment towards
different T-helper subsets
CD8+ T Cytotoxic Cell – Recognition of foreign/mismatched donor
antigens via alloantigen HLA-I-TCR
complex (usually on nucleated cells)34
– Direct cytotoxic lysis: allogeneic graft
clearance
*Up-regulation of CTLA-4 or
PD-1 contribute to inhibition of
T cell activation135,140
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hypothesis)15,16, a response that will also trigger additional
adaptive immune responses via specific cytokines leading to
clearance of donor graft cells. NK-mediated killing may be
aggravated by specific culture conditions used during the gen-
eration of stem cell therapies, which might give rise to differ-
entiated cellular products improperly expressing immune
molecules or containing reminiscent molecules of the cell type of
origin17–22 (see “What are the immunological confounders that
should be taken into consideration for stem cell therapy?”).
Conversely, certain tissues might, either naturally or due to the
inflammatory setting generated at the time of transplantation,
express inhibitory ligands or cytokines at high levels which might
compensate for the degree of HLA-mismatch. This has been
shown for HLA-C, HLA-E up-regulation or IL-10 secretion in
hPSC-retinal pigment epithelial (RPE) cells23–25. In fact, recent
works have demonstrated that the incorporation of specific NK
inhibitory ligands (e.g., HLA-E, CD47) into the cellular therapies
can ameliorate NK cell graft response26–28 (see “How can
immunogenicity be overcome or ameliorated for the long-term
success of cellular therapies?”).
The complement system, composed of more than 30 soluble
and cell-bound proteins29, is another major component of the
innate immune system. Its relevance is illustrated by the finding
that the success of islet and hepatocyte cell transplants is limited
by activation of the complement and coagulation cascades30,31.
Also, hiPSC-RPE cells have shown to produce several comple-
ment components which, under inflammatory or stress condi-
tions, had a significant impact on RPE cell survival and function
in a therapeutic setting32,33.
In the context of transplantation, adaptive immunity is trig-
gered by the recognition of foreign/donor antigens by recipient
T cells. This is mostly due to the expression of highly poly-
morphic MHC molecules leading to T cell-mediated immune
response and rejection of the transplanted allogeneic cells34,35
(Table 2). In general, HLA-I-peptide complexes (expressed on a
majority of nucleated cells) are recognized by CD8+ cytotoxic
T cells and following activation they mediate the direct killing of
the target cells; whereas HLA-II molecules expressed mainly on
antigen presenting cells (APC) present peptide derived from
exogenous antigens to CD4+ helper T cells, leading to the acti-
vation of other immune cells including cytotoxic T cells and B
cells36. Transplanted cells can activate the adaptive immune
system (alloreactive T cells) through three pathways of
allorecognition34,37 (Fig. 2). In the direct pathway of allor-
ecognition, recipient CD8+ and CD4+ T cells recognize HLA-I or
II-allo-peptide complexes, respectively, on donor APCs/cellular
therapy which are consequently activated. In the indirect pathway
of allorecognition, donor allo-peptide is processed by recipient
APCs and presented to mainly CD4+ T cells. In the semi-direct
pathway, intact donor HLA-I and -II-allo-peptide complexes are
internalized, transferred to the membrane of recipient APCs, and
presented to CD8+ or CD4+ T cells for their activation38. Acti-
vated recipient CD4+ T cells (with direct or indirect specificity)
can provide help to cytotoxic CD8+ T cells with direct allospe-
cificity to kill donor cells by recognizing allo-HLA-I molecules on
their surface (typically leading to acute rejection); in addition to
activating other immune cells e.g., NK cells and B cells which in
turn will produce allograft-specific antibodies (typically leading to
chronic rejection)39,40. In fact, different degrees of mismatch
would be anticipated to result in different rejection strengths, as
has been shown by Sugita and colleagues when allogeneic hiPSC-
RPE cells with homozygous HLA-A, -B, -DRB1 alleles greatly
reduced both in vitro and in vivo immune responses41,42.
Because most regenerative cellular therapies are not expected to
contain donor HLA-expressing APCs, it is anticipated that indirect
and semi-direct allorecognition will dominate the adaptive
immune response to regenerative cellular therapies. However,
remnant embryonic antigens such as TRA-1, SSEA3 expressed by
cellular therapies (even in an isograft setting) with direct T cell
activating capability may be able to elicit an immune response.
Therefore, although certain cellular products would be expected to
activate the adaptive immunity directly, the majority would be
expected to activate the indirect and semi-direct mechanisms of
allorecognition through recipient dendritic cells (DC) or macro-
phages that would recognize either alive or dead donor grafted cells
and present their respective allo-antigens to T cells (via processing
and presentation of donor antigens or following the transfer of
intact donor HLA-allo-peptide complexes)38. Nonetheless the up-
regulation of certain inhibitory T cell ligands (e.g., PD-L1, CD95),
the secretion of specific molecules such as pigment epithelium-
derived factor (PEDF), IL-10, TGFβ, or the induction of
alloantigen-specific regulatory T cells (Tregs), that may be inherent
to the immunosuppressive phenotype of a specific cell type or
occur under specific inflammatory conditions and cytokines (e.g.,
IFN-γ), could favor the inactivation of T cells even in the presence
of a degree of HLA-mismatch23,25,41–46. Taking advantage of this,
Yoshihara et al. elegantly over-expressed PD-L1 and showed long-
term survival of the injected edited human islet-like xenografts.
These xenografts restored glucose homeostasis in immune-
competent diabetic mice for 50 days, and upon ex vivo IFN-γ
stimulation, they showed restricted T cell activation and graft
rejection compared to non-engineered cells47.
Conversely, the presence of inflammatory molecules (particu-
larly IFN-γ) may induce the up-regulation of HLA-II molecules
in the cellular therapies, which would mainly trigger the
direct pathway of allograft rejection via CD4+ cells leading to
B cell activation, as shown by multiple studies in hPSC-
RPE23–25,41,42,45. Despite the intense historical interest in study-
ing the impact of knocking out HLA genes on immunogenicity,
recent advances in genetic engineering tools have finally provided
a robust platform for several groups to very attractively generate
cells lacking HLA genes specifically aimed at developing universal
Table 2 (continued)
Main component Dominant stimuli Effector functions
B Cell and Antibodies – Amplification of the indirect response to
donor alloantigens upon their activation
by CD4+ T cells in germinal centers (e.g.,
lymph nodes, spleen)10–14
– Generation of antigen-specific
antibodies (humoral immunity)
– Driving of T cell activation
– Modulation of innate and adaptive
immune system activation by
releasing pro- and anti-inflammatory
cytokines, e.g., TNFα, IL-6, IL-10,
CCL22 and CCLl7
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cellular therapies for regenerative medicine23,48. However, this
strategy particularly intended at abolishing T-cell responses may
eventually lead to NK cell activation and graft rejection, hence
opening a novel window for future therapeutic strategies aiming
to keep both adaptive and innate immune systems under control
(see “How can immunogenicity be overcome or ameliorated for
the long-term success of cellular therapies?”).
What are the available experimental platforms to study the
immunogenicity of cellular therapies in vitro and in vivo?
An increasing broad range of in vitro and in vivo experimental
approaches are available to investigate the immune response to
cellular therapies. Due to the complexity of the immune system
and the inherent deficiencies of all methodologies, it is almost
always necessary to combine data from several in vitro techniques
and in vivo models in order to reach definitive conclusions on the
immunogenicity of cellular therapy (Table 3). However, it is not
usually feasible for a research group to incorporate the complete
range of in vitro and in vivo methodologies into every study.
Thus, the assessment of the response of a particular immune
compartment is often the focus of individual studies. Here we
describe a summary of the most utilized methods to compre-
hensively evaluate the immunogenicity of cellular therapies.
In vitro methodologies to assess the immunogenicity of cellular
therapies.
Assessment of innate immunity
NK responses to a cellular therapy can be assessed by
measurement of NK activation or degranulation (i.e., lytic
granule trafficking), cytokine release, and NK cytotoxic
killing. NK cell degranulation assays are usually performed
by co-culturing human pre-activated NK cells and target
cells (cellular therapy) in an assay-dependent ratio.
Degranulation is typically evaluated by the expression of
CD107 (lysosomal-associated membrane protein 1/LAMP-
1) molecule and intracellular cytokines (e.g., IFN-γ) in
different subsets of NK cells, which can be co-labeled with
specific KIR-ligands. Cytotoxic activity of NK cells towards a
target cell can be measured in vitro by quantifying the
release of naturally occurring substances (e.g., lactate
dehydrogenase), or through the use of target cells labeled
with radioactive compounds, such as 51Chromium- or
111Indium, which are released upon NK cell killing49,50.
Alternative methods to measure NK cell cytotoxicity include
flow cytometry (e.g., intracellular levels of perforin,
granzymes, and granulysin), enzyme-linked immunosorbent
assay (ELISA)-based granzyme measurement, image cyto-
metry, and morphometric analysis by microscopy51,52.
Additionally, NK cell-mediated cytolysis and antibody-
dependent cellular toxicity (ADCC) can also be studied in
a novel label-free, non-invasive manner using image
cytometry or a microelectronic sensor measuring impedance
in adherent cells, thus avoiding the use of radioisotopes53,54.
Despite these novel methods, most studies assessing NK
activation by PSC aimed as genetically engineered-
hypoimmunogenic cellular therapies used 51Chromium
release assays, which illustrated the decrease in NK cell
cytotoxic levels of the respective gene editing
approaches26–28,55 (see section “How can immunogenicity
be overcome or ameliorated for the long-term success of
cellular therapies?”).
To complement the evaluation of the innate immune
system, some studies have assessed by flow cytometry or
immunofluorescence (IF) staining the expression of activat-
ing or inhibitory ligand molecules that might be expressed
by the hPSC-derived cells. These, for instance, include HLA-
A, B, C, CD112, CD155, PCNA, and NKG2A shown by
Petrus-Reurer et al. in hESC-RPE cells23; or NKG2D,
NKp80, NKp16, NKp44, and NKp30 shown by Deuse
et al. in hiPSCs, hi-endothelial-like cells and hi-
cardiomyocyte-like cells26. Although no conclusive ligand
expression differences were found between edited and
respective wild-type counterparts in these studies, their
unique expression and combined downstream signal inter-
action might explain some of the mechanisms driving NK
cell activity in specific cell lineages57,58.
Assessment of other components of the innate immune
response includes analysis of pattern recognition receptors
(PRR) by qPCR before and after stimulation with pro-
inflammatory cytokines as shown by Fischer et al. with
human iPSC-Hepatocytes59. However, the majority of the
studies regarding PRRs have so far been aimed to define a
better infectious disease model rather than defining the
contribution of PRRs in cell rejection. Key components of
the complement cascade (Collectin-11, MASP2, C3d, C5B-9
(mac), CFB) have been analyzed before and after cell stress
or pre-conditioning with TNF-α or IFN-γ32,33. A pioneering
study from Sugita et al. showed by using different assays
(flow cytometry, RT-PCR, and ELISA) that iPSC-RPEs
expressed key components of the complement cascade that
are up-regulated by IFN-γ and T Helper-1 mediated
responses32. A few years later, Fanelli et al. showed by
immunohistochemistry (IHC) and western blotting that
in vitro cultured hiPSC-RPE under hypoxic stress upregu-
lated their surface expression and the release of collectin-11,
a molecule triggering complement activation33.
Fig. 1 The innate Immune system. NK cell activation or inactivation following
activating or inhibiting receptor-target cell ligand signaling. A mismatched/
lack of HLA-I-Antigen complex is a strong NK cell-activating signal. Once
activated, a cytotoxic response will follow mainly through granule release.
HLA: human leukocyte antigen, NK: natural killer.
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Assessment of cell-mediated T cell activation
The most commonly used in vitro methodology to study the
response of T cells with direct allospecificity to a specific
cellular therapy is a co-culture system with the cells of
interest and allogeneic peripheral blood mononuclear cells
(PBMCs). To try and mimic the indirect alloresponse,
monocyte-derived DCs can be co-cultured with autologous
T cells in the presence of the cellular product61. However,
the indirect (and semi-direct) allorecognition is best
modeled in vivo as it takes time for this pathway to emerge
after antigen exposure. Experimental end-points for these
co-culture assays comprise immune cell proliferation,
expression of activation markers, target cell killing, and
cytokine production. These assays are usually complemen-
ted with the evaluation of the expression of HLA and co-
stimulatory and co-inhibitory molecules on the cellular
product (Table 3). T cell proliferation measured in these
assays can be coupled to the evaluation of naïve, activated,
central and effector memory T cell sub-populations using
specific markers62, thus providing a more comprehensive
evaluation of the target T cells activated by the cellular
product25,40,42,63–68. To understand how the inflammatory
microenvironment influences a cellular therapy and its
capacity to activate T cells, co-cultures can be executed
Fig. 2 The adaptive immune system. Illustration representing the three different pathways of allorecognition. The direct pathway of allorecognition typically
involves recognition of intact HLA-I or -II-Antigen complexes expressed by donor DC (i.e., APC)/cellular therapies by recipient CD4+ or CD8+ cells,
respectively, usually leading to acute graft rejection. T cells with direct allospecificity are present in all individuals at very high frequency and this pathway is
thought to play a major role immediately following transplantation. The indirect pathway of allorecognition involves processing and presentation of donor
HLA molecules by recipient DC (i.e., APC) to recipient CD4+ T cells, which then provide help for CD8+ T cell-mediated cytotoxic killing and antibody
production by B cells. The frequency of T cells with indirect allospecificity is undetectable but increases with time from the transplant. In line with this, this
pathway was thought to be the most relevant for graft rejection late post-transplant. The semi-direct pathway involves the transfer of intact donor-derived
HLA molecules to recipient APC leading to CD8+ or CD4+ T cell activation. This latter pathway implies that the direct pathway of allorecognition lasts for
longer than what was initially thought and indicates that the same recipient DC can present directly and indirectly donor HLA molecules to host T cells. In
all pathways, the activated recipient CD4+ T cells provide help for activation of cytotoxic CD8+ T cells which kill donor cells by binding to allo-HLA-I on
their surface then leading to cellular-mediated rejection of cellular therapy (typically acute reaction). In addition, activated CD4+ T cells will trigger the
innate immune system, inflammation, and B cell maturation into plasma cells that will produce allo-antigen specific antibodies which will lead to an
antibody-mediated rejection of the cellular therapy (typically chronic rejection). Cellular therapy: refers to an HLA-II expressing target cell, DC: dendritic
cell, TCR: T cell receptor, HLA: human leukocyte antigen, NK: natural killer.
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following pre-conditioning of the hPSC-derived product
with pro-inflammatory cytokines such as IFN-γ, TNF-α, and
IL-1β (Table 3). Generally, co-cultures of the cellular
therapies with PBMCs or isolated CD4+ or CD8+ tracker-
labeled (e.g., CFSE) to assess T cell proliferation or IFN-γ
measurements in the supernatants to assess T cell activation
has been the most utilized approach to evaluate the
immunogenicity of cellular therapies from matched, mis-
matched or genetically modified donor cells23,40–42,45,48,55.
And in fact, most cellular products tested in this manner
have shown little or no immunogenicity, thus confirming
their inability to directly activate the adaptive immune
system. Specifically, by co-culturing PBMCs with hESC-
RPEs pre-stimulated with IFN-γ, Petrus-Reurer et al. have
recently shown their lack of immunogenicity unless cultured
with very specific conditions (e.g., particular target:immune
cell ratio, presence of cytokines and activating molecules). In
a similar manner, this lack of immunogenicity in vitro has
also been shown for other cell types like hiPSC-derived
cartilages69. Recently, Mehler et al. showed that hiPSC-
derived neural crest stem (NCS) cells induced negligible
CD3+ T cell proliferation although, conversely, hiPSC-
derived smooth muscle cells (SMC) favored a high level of
cell proliferation65.
Assessment of the immunomodulatory function of the
cellular therapy
Indeed, in contrast to immune activation, suppression of T-
cell responses in vitro has been described for several cellular
products (Table 3). Typically, this ‘immunomodulatory’
potential is assessed by quantifying the impact of the cellular
therapy on T cell proliferation in the presence of molecules
that would induce it (e.g., soluble antibodies anti-CD3/
OKT-3, coated beads, IL-2)23. Assessment of expression of
co-stimulatory molecules (inhibitory: e.g., PD-L1, PD-L2;
activating: e.g., CD80, CD86) by the cellular therapy as
shown by several studies is also relevant, as this may confer
T cell inhibitory properties and explain some of the
inhibition of T cell proliferation and cytokine production
observed in the co-culture in vitro assays63,70–73. Petrus-
Reurer et al. have shown that pre-IFN-γ stimulated hESC-
RPEs significantly suppressed both CD8+ and CD4+ T cell
proliferation in the presence of OKT-3, a mechanism that
might be mediated by the up-regulation of specific co-
inhibitory molecules in the absence of co-stimulatory
molecules. Similarly, hPSC-derived retinal ganglion cells
had the ability to inhibit T cell proliferation in a
transforming growth factor (TGF)-β2 dependent way74.
TGF-β production by hiPSC-NCS is crucial for mediating
their T cell proliferation immunosuppressive capacity as
shown by Fujii et al67. However, by using different
experimental conditions (e.g., source of hiPSC, NCS
differentiation protocol, length and readout of the MLR),
Mehler et al. showed the lack of this capacity for hiPSC-NCS
cells. The opposite results obtained in these two studies
highlight the importance of the immunological confounders
present at the time of performing the different in vitro and
in vivo assays (see “What are the immunological con-
founders that should be taken into consideration for stem
cell therapy?”).
In vivo methodologies to assess the immunogenicity of hPSC-
derivatives. Availability of optimized and representative in vivo
animal models are a limiting factor for the definitive study of
the immunogenicity of regenerative cellular therapies. Human
cellular products have been previously transplanted into different
anatomical locations using xeno- and immunodeficient
animal models (e.g., rodents, lagomorphs, pigs, non-human
primates)23,41,75,76. Despite species differences, these studies have
been very useful in understanding the basic mechanisms of the
host response. However, as these models do not replicate the
human immune response to human cellular therapies, their
ultimate utility for clinical translation is somewhat limited and
they will not be further discussed in this review.
There are a number of effective strategies to model a
competent human immune compartment in vivo in order to
assess the immunogenicity of cellular therapies77–80. In essence,
these models involve the reconstitution of severely immunodefi-
cient rodents with human immune cells. The human immune
cells used for reconstitution of the mice can either be in the form
of adoptively transferred mature lymphocytes (PBMCs) or
generated de novo by transfer of CD34+ hematopoietic cells.
Mature lymphocytes are usually obtained from the peripheral
blood of human donors, although the spleen of deceased
transplant organ donors has recently been identified as an
alternative source81. Alternatively, CD34+ HSCs can be obtained
from umbilical cord blood, bone marrow, or fetal liver. The most
common strain of mouse used for the generation of these
“humanized” or human immune system (HIS) mice is NOD scid
gamma (NSG) mice which lack mature B, T, and NK cells. It is
important to note that the immune compartment generated in
HIS mouse models is “suboptimal”, and a number of different
strategies have emerged to augment and improve the immune
response mounted by the animals. These include co-
transplantation of fetal human thymic or other tissue and the
use of genetically modified mice expressing human cytokines,
HLA, or other important signaling molecules. The range of
available humanized mouse models and their relative advantages
and disadvantages has been reviewed in multiple studies77–80,
and are also summarized in Fig. 3.
A further challenge is the occurrence of graft-versus-host
(GvH) reaction which limits the experimental time-window82.
This window is dependent on the HIS model and mouse strain
used and is most limited in the PBMC model. Critical in
interpreting the observed immune response is the use of positive
and negative control tissues/cells. Positive control cells should
ideally be “adult” cells and tissues that may represent an
alternative treatment to cellular therapy. Where possible,
autologous cells/tissues are the ideal negative controls although
practically this is rarely possible. Lastly, the HIS models are
subject to significant biological variation and large group sizes
may be necessary to draw definitive conclusions. However, the
generation of HIS mice from the spleen of deceased transplant
organ donors, together with the use of control cells and
generation of cellular therapies from the same donor, has the
potential to address some of these challenges81.
The in vivo immunogenicity of hPSC-cell grafts can be
quantified using a range of experimental endpoints, which have
been summarized below from a variety of studies evaluating stem
cell therapies (Table 3):
● Assessment of survival/immune destruction of the
transplanted cells by luciferase, specific human- or
tissue-specific markers on IHC/immunofluorescence
(IF)23,26–28,39,40,55,66.
● Immune characterization of the transplanted cells (e.g.,
upregulation of immune markers such as HLA-I and -II, or
the above-mentioned T cell and NK cell activating and
inhibitory ligands) by flow cytometry or IHC/IF23,28,41.
● Phenotypic characterization of the immune infiltration (type
and amount), e.g., CD3+/CD4+/CD8+ T cells4,5,64,66,68,83;
CD56+ NK cells; RAM11+ macrophages; HLA-II+ APCs by
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flow cytometry or IHC/IF to evaluate the immune responses
elicited by the graft23,28,39,66.
● Systemic cellular immune response (e.g., increase in the
number of lymphocytes in spleen) or change in phenotype
assessed by flow cytometry and IHC/IF for specific T cell
and NK cell populations, but also assessment of splenic
germinal center formation for B cells or deposition of
complement molecules14, DAMP secretome by IHC/IF66.
● Systemic anti-human antibody-mediated response assessed
by flow cytometry or Luminex assays of the transplanted
mice sera23,32,40.
● Evaluation of the main complement molecules (e.g., C3,
C5, CFH/B/I, CL-11, C3d, and C5b-9) present in the host
serum or deposited at the site of the graft, measured by
ELISA and/or IHC32,33.
The combination of all the described assays would be the
ideal approach to get the full picture of the immune response
induced in vivo, but often it is not possible and only some of the
mentioned endpoints are analyzed. As an exemplar study,
Petrus-Reurer et al. evaluated the immunogenicity of unedited
wild-type and edited hESC-RPE lacking HLA-I and -II
molecules injected in the subretinal space of albino rabbits.
They assessed the survival of engrafted human cells, immune
marker expression (HLA-I, HLA-II), and immune response
(CD3, CD56, RAM11) with IF. Furthermore, they evaluated
specific anti-human antibody production by incubation of
rabbit sera that received the cellular therapies with hESC-RPE
ex vivo further mixed with anti-rabbit fluorescent antibodies
analyzed by flow cytometry. Overall, this study demonstrated
decreased early and delayed late immune responses of HLA-I
Fig. 3 Humanized mice models for the in vivo immunological assessment of cellular therapies. Illustration representing the methodologies behind current
humanized mice models highlighting the advantages (check) and disadvantages (cross) of each model. The models include: the human peripheral blood
lymphocytes (Hu-PBL-SCID) in which most of the engrafting cells are human T cells that express an activated phenotype while few B cells or myeloid cells
engraft. One caveat is that these mice will develop a xenogeneic graft-versus-host disease (xeno-GVHD) that results in death, but xeno-GVHD can be
delayed using immunodeficient mice lacking mouse MHC class I or class II; the human stem cell repopulating cell (Hu-SRC-SCID), which is established by
engraftment of human hematopoietic stem cells (HSC) derived from bone marrow, umbilical cord blood, fetal liver, or mobilized peripheral blood HSC.
Engrafting mature adult immunodeficient IL2rγ null mice with HSC permits the generation of multiple hematopoietic cell lineages but few T cells while
human T cells are readily generated following engraftment of newborn or 3–4 week-old NSG and NOG mice with HSC; the SCID-HU, which is established by
implantation of human fetal liver and thymus fragments under the renal capsule of immunodeficient mice and a major limitation is the paucity of human
hematopoietic and immune cells in the peripheral tissues; and the bone marrow, liver, thymus (BLT), which is established by implantation of human fetal liver
and thymus fragments under the renal capsule of sublethally irradiated immunodeficient mice accompanied by intravenous injection of autologous fetal liver
HSC. The use of immunodeficient NOD-scid mice to establish the BLT model led to human immune system engrafted mice, which is further enhanced by the
engraftment of NSG mice. A complete hematopoietic and immune system develops, and the human T cells are educated on a human thymus and are HLA-
restricted. IP: intraperitoneal, IV: intravenous, IS: intrasplenic, IF: intrafemoral, IC: intracardiac, IH: intrahepatic, GvHd: graft versus host disease.
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and -II knockout hESC-RPE compared to wild-type cells in a
xenograft model without immunesuppression23.
These assessments can also be complemented by the use of
real-time imaging techniques (e.g., using luciferase constructs,
spectral domain-optical coherence tomography [SD-OCT] scans
in the retina) or behavioral assays for dopaminergic cells as
alternative methods to assess immune infiltration, graft cell
survival, and/or function of the cellular therapy in the site of
injection. This has been elegantly shown by several groups
exploring survival and function of e.g., hypoimmunogenic hiPSC/
hESC-RPE cells to be used as an alternative treatment modality
for age-related macular degeneration23,26,28.
What are the immunological confounders that should be
taken into consideration for stem cell therapy?
There are several confounders, both cell-related and assay-related,
that should be taken into consideration when evaluating the
immune response to any cellular product (Fig. 4).
The original source of the cell product has a potentially
important impact. There are two common sources of pluripotent
cells: hESCs and hiPSCs84–87. As hESCs and hiPSCs require
different methodologies to generate the differentiated final cell
product, it is, therefore, possible that they may express different
antigens leading to different immunogenicity. Specifically, several
factors present in the differentiation protocols and in vitro culture
conditions may be sources of xeno or aberrant immunogenic
antigens. Such expression can result from prolonged cultures in
animal product-containing media, such as the uptake of the non-
human sialic acid N-glycolyneuraminic acid (Neu5Gc) by hESC
when cultured in standard conditions with serum88–91. Non-
physiological media constituents, such as high concentrations of
growth hormones or antibiotics have also been shown to induce
the ectopic expression of CD3092,93. Finally, chromosomal
abnormalities have been shown to be produced through in vitro
propagation of hESC lines in multiple studies94–97.
Another important confounder that may impact rejection is
the expression of potentially immunogenic or immunomodula-
tory surface molecules and the release of soluble mediators. All
these factors can be dependent on the differentiation or
maturation state of the cells, independently of their cellular
source. Specifically, accelerated in vitro differentiation processes
might be associated with immunological immaturity, since it is
well established that somatic cells acquire such maturity during
fetal development that continues after birth in a process mediated
by intricate and gradual feedback mechanisms between the nas-
cent immune system and developing somatic cells98,99. This
process will dictate and shape the repertoire of activating and
inhibitory signals that would then orchestrate the immune sys-
tem. Such fine-tuning is unlikely to occur in vitro with meth-
odologies that recapitulate long periods of normal development in
just a few weeks, and also in the absence of biologically normal
immune cell interactions. This may result in incompletely dif-
ferentiated cells that may express ligands reminiscent of an
embryonic origin that could potentially be retained and recog-
nized as foreign antigens, such as early glycans, proteins, or other
unique surface molecule modifications (e.g., TRA-1-81, TRA-1-
60, SSEA3, SSEA4) that were not present during immune edu-
cation of the recipient’s immune system in an already-mature
antigenic microenvironment17–19. As mentioned in previous
sections, incompletely differentiated cells may also lack or exhibit
a reduced expression of ligands that are essential for immune cell
inhibition, including reduced expression of HLA-I (easily altered
in in vitro conditions due to its complex regulation and response
to inflammatory cytokines20,21), or absence/presence of specific
KIR-ligands in the recipient’s NK cells that were not properly
educated to recognize certain HLA-I epitopes as self22,100,101.
Conversely, expression of other ligands such as HLA-E and
HLA-G, which are known to confer foeto-maternal tolerance,
may be maintained and may protect the product against NK cell
cytotoxicity102. Some of these mechanisms have been exploited by
groups attempting to reduce cellular product rejection27,28 (see
“How can immunogenicity be overcome or ameliorated for the
long-term success of cellular therapies?”). Other immunomodu-
latory mechanisms, reminiscent of those contributing to foeto-
maternal tolerance could include: secretion of Arginase I resulting
in decreased CD3 expression and lymphocyte proliferation103,
activation of hemoxygenase I enzyme to produce anti-
inflammatory molecules104, expression of high levels of cathe-
psin B and a serine protease inhibitor (serpin, SPI-9) that allows
the destruction of granzyme-B released by T cells and NK cells105,
or expression of the Fas ligand (FasL, CD95L) resulting in T cell
apoptosis106–109.
In contrast to hESC-derived cells, the reprogramming proce-
dure for the generation of hIPSCs could result in aberrant antigen
presentation due to partial epigenetic memory retained from the
Fig. 4 Immunological confounders of cellular therapies. Illustration representing the immunological confounders involved in cellular therapies including
factors concerning various aspects of the cell therapy (e.g., cell source, differentiation protocol, cell type/function, specific maturation state of the cell
product), the recipient’s transplantation site, and the limitations inherent to in vitro and in vivo experimental platforms. Overall these factors might trigger
different degrees of rejection in the patient that will receive the cellular therapy, therefore limiting its efficacy.
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parental induced cells. This could produce chimeric surface
molecules of more than one cell type, thus eliciting an immune
response even in autologous transplants66,110.
Some cellular therapies may require further differentiation
or maturation in vivo through interaction with other immune or
neighboring cells, as well as through exposure to blood flow or
tissue mechanics. It is therefore likely that in some cases
the immunogenicity captured in vitro may not fully recapitulate
the immune response ultimately observed in vivo. Examples
include stem cell-derived β-like cells needing in vivo cues from
the islet niche to reach a fully mature and specialized state111–113,
or dopaminergic neurons that must undergo further maturation
after transplantation in the midbrain compartment114. Of note,
immunosuppression treatment may have a detrimental effect on
this process, either directly or by modifying the immune micro-
environment, but further work is required to quantify these
effects.
Cellular therapies may be less prone to immune rejection
where the derived cells inherently have an immunomodulatory
immuno-protective function. Examples include cells acting as
anatomical barriers (e.g., certain types of endothelial cells,
astrocytes, or pericytes in the blood-brain barrier) or RPEs in the
blood-retinal barrier (which endogenously express ligands such as
PD-L1, CD95L, or secreted molecules as PEDF, TGF-β3, IL-
10)25,43–45. Similarly, transplantation of cellular therapies in
immune-privileged anatomical niches (e.g., eye, brain, testes, or
placenta), may induce different immune responses. If not com-
promised by the specific disease or by the process of transplan-
tation, such sites may confer an advantage for allogeneic donor
cell engraftment.
How can immunogenicity be overcome or ameliorated for the
long-term success of cellular therapies?
A small number of early-stage hPSC-based clinical trials for
multiple diseases are currently underway (Table 1). As classical
immunosuppression is associated with a range of side effects6, a
number of strategies are being explored to reduce or eliminate the
immunogenicity of stem cell-derived cellular therapies (Table 4).
Immunosuppressive agents. Immunosuppression is the current
standard approach to prevent the rejection of solid organ trans-
plants. This strategy has also been adopted by recent clinical trials
to prevent the rejection of cellular therapies (Table 1). In general,
there are five broad classes of immunosuppressant drugs:
(i) glucocorticoids/steroids (e.g., prednisolone, dexamethasone,
Table 4 Current strategies to ameliorate immune response upon transplantation of allogeneic cellular derivatives.
Strategy Principle Limitations References
Immunosuppression Use of drugs targeting essential pathways for
immune cell performance.
– Cytotoxic effects
– Vulnerable recipient’s immune system
115–119
Types: glucocorticoids/steroids, cytostatics,
specific antibodies, drugs acting on
immunophilins/other mechanisms
HLA matching HLA-typed cell banks that allow the matching
of donor and recipient cells using homozygous
cell lines with frequent HLA haplotypes.
– Minor alleles not matched
– Might require immunosuppression
126–128
Examples: United Kingdom, Japan
Genetically
modified Cells
Genetically engineered cells with gene editing
techniques (e.g., CRISPR/Cas9, TALENS) that
would bypass specific immune mechanisms of
action.
– Safety concerns: 23,26,27,55,132
• Off-target effects of targeting
Examples: HLA-I or/and -II knock out cell
lines, HLA-C retained lines, immune
cloaked cells
• Conversion to malignant/infected cell
that will not be recognized
Immune Tolerance A combination of deletion, cell-intrinsic
checkpoints, and suppression by regulatory
mechanisms.
– Specificity of the inhibitory drug
(costimulatory and adhesion blockade)
47,143–147,150
Examples: costimulatory and adhesion
blockade, inhibitory ligand overexpression,
adoptive cell therapy with naturally occurring
Tregs/induced donor-specific Tregs
– Genetic engineering/viral off-targets
(ligand overexpression)
– Cost and infrastructure needed per
patient (adoptive therapy)
Cell Shielding Protection or shielding of the derived cells
with specific materials or encapsulation
devices
– Immunocompatible materials 153,154,156–158,160,162,164–166




– Permeability to essential soluble
factors
ViaCyte: https://viacyte.com/
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hydrocortisone) that act by reducing inflammation; (ii) cytostatics
(e.g., alkylating, antimetabolites, methotrexate, azathioprine, and
mercaptopurine, cytotoxic antibiotics) that block T cell pro-
liferation; (iii) specific antibodies (polyclonal, monoclonal, anti-T
cell receptor, anti-IL-2 receptor) that deplete subsets of immune
cells such as macrophages/APC, T cells and/or B cells; (iv) drugs
acting on immunophilins (e.g., cyclosporine, tacrolimus, sir-
olimus, everolimus) that inhibit cytokine production by for
instance calcineurin inhibitors; and (v) drugs with other
mechanisms of actions (e.g., interferons, opioids, TNF binding
proteins, mycophenolate, and small biological agents)120,121.
While classical immunosuppressive drugs are an appealing
choice to reduce rejection of cellular therapies, they are known to
lead to potentially serious toxic side-effects, including increased
risk of infection (e.g., viral, bacterial, or fungal), cancers (e.g., skin
or lymphoma), and organ damage (e.g., renal failure)6,122–124.
Moreover, classical immunosuppressive drugs do not specifically
and effectively modulate the innate immune response. Also, it is
unclear what impact, if any, immunosuppression may have on
cell survival, maturation, and function following transplantation
of the differentiated cells aimed for cellular therapy. Similarly, it is
still not clear if a different regime would need to be used
depending on the hESC or hiPSC origin of the cellular source.
Until now, clinical studies using stem cell therapies either opted
for local suppression (e.g., corticosteroids) or more general
regimes of immunosuppression (e.g., cyclosporine, MMF, tacro-
limus) (Table 4). These regimes have not been fine-tuned as they
were aimed to maximally avoid donor cell rejection. Therefore,
the use of immunosuppressive agents in the context of cellular
therapies requires further investigation to bypass toxic side-effects
in the recipients, and it is generally accepted that the development
of more specific strategies to reduce immune-mediated rejection
of cellular therapies is desirable.
HLA-matching. Clinical outcomes after solid-organ transplan-
tation are dependent on the degree of HLA disparity between the
donor and the recipient7,125. Development of HLA-typed cell
banks that allow optimal matching of donor and recipient cells
represents an attractive strategy to reduce the risk of immune
rejection. This approach is particularly attractive for populations
in which major HLA-alleles are relatively conserved. The required
degree of matching will differ depending on the cell type of
interest (e.g., whether HLA-II is expressed by the cells) and the
site of transplantation. It is estimated that a total of 150 or 140
cell lines would be required to provide well-matched cellular
therapies for 93% or 90% of the UK and Japanese populations,
respectively126–128. It is important to note, however, that the
generation of cell banks with sufficient diversity for large and
heterogeneous populations such as the US will be challenging.
Moreover, the risk of rejection would still remain due to the
presence of mismatched minor HLA antigens. Also, patients with
less common haplotypes would remain difficult to match and
alternative strategies would be needed to prevent rejection. This
approach has not been tested yet with regenerative cell therapies
per se but the reduction in immune response using matched
donors is evidenced in solid organ transplants129.
Genetically engineered cells. The emergence of genetic engi-
neering tools such as the CRISPR/Cas9 technology has enabled
the pursuit of low- or non-immunogenic “universal” cellular
therapies. This is predominantly explored through the elimina-
tion of HLA genes (individually or both HLA-I and HLA-II),
most effectively by targeting essential molecules for their correct
location and expression, namely β2M (required for proper
surface expression of HLA-I) and CIITA or RFXANK (master
transcriptional regulators for HLA-II genes)23,48,55. Since HLA is
the predominant driver of the alloimmune response, HLA-knock-
out (HLA-KO) cells are expected to evade CD8+ and CD4+ T cell
responses. However, HLA-I deficient cells may nonetheless acti-
vate recipient NK cells (triggered by the “missing-self” signal),
thus posing an obstacle for successful transplantation. To over-
come this, engineered cells overexpressing non-polymorphic
HLA-I molecules such as HLA-E, HLA-F, and HLA-G, acting
as inhibitors of NK cell-mediated lysis via NKG2A/CD94 (HLA-
E), KIR2DL4, and ILT2 (HLA-G) receptors have been generated.
This approach has been shown to have at least some efficacy in
enabling allogeneic cells to escape immune attack in vitro and in
xenotransplantation experiments, as shown with hPSC, hESC-
RPE, and hESC-neural progenitor cells using NK cytotoxic/
51Chromium release assays27,28,130,131.
An alternative strategy is the generation of cell lines that
express a common allele of a specific polymorphic HLA-I
molecule (HLA-A, -B or -C) that should be matched and that
would then be able to bind NK inhibitory receptors. For example,
HLA-C retained cells that also lack HLA-II demonstrated the
ability to suppress both NK and T cell responses while
maintaining antigen presentation both in vitro and in vivo55.
Another approach used in HLA-KO cells is the induction of
overexpression of CD47 as a potent inhibitor of phagocytosis,
thus avoiding macrophage and NK cell-mediated rejection in
allogeneic hosts. This approach has been exemplified by
demonstrating survival and proliferation of luciferase-labeled
hiPSC and hiPSC-derivative allografts in immunocompetent
mice26. Finally, “immune cloaking” is a more holistic approach
that includes disruption of several pathways of immune activation
and has been attempted by over-expression of immunomodula-
tory transgenes PD-L1, FASL, CD47, CD200, CCL21,MFGE8, H2-
M3, and SPI6 in mouse ESCs, which allowed them to survive
indefinitely as allografts132. Universal non-immunogenic cells
could also be engineered so as not to express auto- or neo-
antigens that normally trigger responses in autoimmune or
genetic diseases.
There are important outstanding safety and efficacy considera-
tions that must be addressed in relation to genetically engineered
cellular therapies. First, it is essential to demonstrate that the cells
do not undergo malignant transformation or infection by virtue
of their ability to evade immune recognition. The addition of a
fail-safe/suicidal gene cassette system has thus been suggested
to selectively eliminate cells that are, for example, more
proliferative133. Second, it is important to demonstrate that the
elimination of HLA (or other) molecules does not interfere with
cell survival, differentiation, and function after transplantation.
Despite the current high interest to adopt such technology by
several pharmaceutical companies, the clinical translation of this
promising approach is still immature and requires careful study
in the context of a competent HIS to better anticipate the
outcome of clinical trials.
Induction of tolerance. Immune tolerance is defined as the
absence of a deleterious immune response despite the continued
presence of the antigen (e.g., derived from the transplanted cells)
in an intact immune system setting. It is a desirable state that
could potentially be achieved through a combination of specific
deletions, cell-intrinsic checkpoints, and suppression by reg-
ulatory mechanisms such as in vivo induction or expansion of
Tregs134–142. The targeted manipulation of specific T cell co-
stimulatory or inhibitory pathways by for instance inhibiting the
second signal via specific monoclonal antibodies (e.g., anti-
CD40L, CTLA4Ig, anti-LFA-1), might represent a way to induce
tolerance47,143. Another approach to achieve tolerance that has
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recently reached the clinic in solid organ transplantation144–148 is
ex vivo expansion of patient-derived polyclonal or donor-specific
Tregs that would be transferred back to the recipient149–152. None
of these approaches have been directly tested in the context of
regenerative cell therapies. Nonetheless, they are promising
strategies to efficiently regulate the recipient’s immune system in
the long term with minimal induction of toxic effects.
Cell shielding/encapsulation. Shielding of the cellular therapy
with alginate-beads or specific encapsulation devices has been
used for transplantation of β-like cells153–156. Excitingly, the
company ViaCyte has developed different cell-encapsulated ver-
sions of SC-derived human pancreatic progenitor cells to treat
Type 1 Diabetes, which has now entered Phase 2 clinical trials
(https://viacyte.com/). However, the challenge remains on the
maintenance of full oxygenation and vascularization of the cells
for optimal function, while still providing sufficient immuno-
protection over time. This has been largely achieved with mate-
rials of particular permeability and with a specific size and
distribution of nanopores157. In addition, the use of such tech-
nology critically depends on the transplantation site and its
accessibility to the recipient’s immune system, which if protected
(e.g., immunoprivileged sites), might confer natural tolerance of
the grafted cells. Finally, a potentially more refined approach
would be to incorporate biocompatible materials in the matrix
that contains molecules (e.g., anti-inflammatory cytokines,
blocking antibodies) that would protect the cell product against
the recipient’s immune response. This technology is still in its
infancy, but in proof-of-concept studies, hydrogels functionalized
with IFN-γ, TGF-β1, or IL-10 siRNA were able to effectively
modulate the immune response to several immune cells
types158–166. This represents an elegant strategy free of both
in vitro and ex vivo manipulation, although the challenge might
be keeping the cellular therapy free from immune invasion as the
biocompatible material degrades.
In conclusion, while none of the above-mentioned approaches
are perfect on their own, they may be combined synergistically to
minimize immunogenicity. An example of such a combined
strategy may be to use engineered cells or HLA-typed cells
transplanted with low-dose immunosuppression or with strate-
gies to induce tolerance while under a specific shielding material.
Such combinations would be patient-dependent (e.g., if suffering
from a precondition that prevents the use of immunosuppres-
sants), cellular therapy-dependent (e.g., if a cell type is specially
affected by the genetic manipulation or the immunosuppressive
regime), and site-dependent (e.g., in an immune-privileged site,
use of shielding material may not be necessary). In summary, a
bespoke and multi-dimensional case-specific approach is likely to
be necessary to avoid graft rejection while guaranteeing the
survival and function of the specific cellular therapy.
Outlook
Concluding remarks: the need for multi-disciplinary approach
and infrastructure for immune-assessment of cellular thera-
pies. As outlined in this review, characterizing and modulating
the immune response to regenerative cellular therapies is an
essential step for their clinical translation. The immune response
is highly complex, consisting of multiple overlapping and inter-
connected pathways (Table 2). A combination of in vitro and
in vivo methodologies must, therefore, be used in concert for the
definitive evaluation of both the innate and adaptive immune
responses (Table 3). Importantly, all experimental paradigms
have inherent weaknesses and advantages, and extrapolation of
the findings to the clinical scenario should be made with caution.
We described several confounders that can affect the conclusions
of immunogenicity studies, including the original cell source,
differentiation procedure, the identity of the cell type of interest,
maturation status, site of transplantation, or methodological
limitations (Fig. 4). This complexity is mirrored by the plethora of
approaches under investigation to ameliorate or eliminate the
immune response to cellular therapies (Table 4). In view of the
redundancy displayed by the immune system, it is likely that a
combined methodology is would be the most feasible and cost-
effective treatment modality.
We conclude that the immunological assessment of cellular
therapies is as necessary as functional or safety verification
prior to clinical translation. Few research groups possess the
complete range of resources, experimental models, and
expertise to conduct the full breadth of studies required to
generate definitive and validated immunogenicity data that
would be relevant to multiple cellular therapies. We, therefore,
suggest that a reasonable and practical approach would be the
establishment of collaborative networks and platforms combin-
ing diverse expertise and infrastructure, which would warrant
standardized methods for their immunogenicity assessment (in
a similar way to the recent global initiative ARDAT for
advanced cell and gene therapies: http://ardat.org/). If sup-
ported by the full breadth of in vitro and in vivo experimental
models currently available, such a consortium approach would
be well placed to plan and execute definitive immunogenicity
studies that ultimately ensure the safe and efficient clinical
translation of any cellular product.
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